Ropes & Gray represented Spyre Therapeutics in a $350 million public offering of 4,117,648 shares of its common stock at a price per share of $85. The offering priced on October 5 and closed on October 7.
Earlier this year, Spyre priced an upsized $403.0 million public offering of 6,500,000 shares of common stock at $62.00 per share.
Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients.
The Ropes & Gray team was led by capital markets partner Tom Danielski.
The team also included strategic transactions associates Blake Timmerman and Vincent Pandolfi.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.